Frontier Pharma: Prostate Cancer Market Quantitative Analysis

1
Frontier Pharma Prostate Cancer - Identifying
and Commercializing First-in-Class Innovation
2
Summary
Exceptionally Large and Innovative Pipeline The
prostate cancer pipeline is among the largest in
the pharmaceutical industry with 484 products in
active development across all stages. The range
of mechanisms of action employed by these
compounds is also highly diverse, especially in
comparison to the existing market landscape.
More pertinently, the degree and proportion of
breakthrough innovations in this pipeline is
exceptional GBI Research analysis identified 174
first-in-class programs in the prostate cancer
pipeline, acting on 122 first-in-class molecular
targets. This accounts for some 36 of all
products with a disclosed molecular target and is
reflective of the high degree of innovation in
this indication. This has far-reaching strategic
implications for all market participants, as,
despite the high attrition rate in prostate
cancer, it is highly likely many of the
first-in-class technologies will reach the market
over the coming decade and may transform the
clinical and commercial landscape. For Further
Details http//www.bigmarketresearch.com/frontie
r-pharma-prostate-cancer-identifying-and-commercia
lizing-first-in-class-innovation-market
3
Report Description

• Alignment of First-in-Class Molecular Target with
  Disease Causation
• One of the key trends in oncology and in prostate
  cancer in particular over the last decade is the
  clinical and commercial impact of targeted
  therapies designed to target proteins in
  signaling pathways that are strongly associated
  with disease progression.
• By aligning the molecular targets for
  therapeutic intervention with disease causation
  and/or propagation, these therapies limit the
  systemic cytotoxic effects whilst inhibiting
  tumor-promoting signaling pathways. Such
  strategies thereby typically achieve superior
  efficacy and safety profiles.
• Our proprietary analyses demonstrate significant
  levels of differentiation as to how well the
  first-in-class products and their respective
  molecular targets align to underlying gene and
  protein level mutations and dysfunction.

4
Report Description

• More advanced analytics further substantiated
  these findings as strong levels of
  differentiation in the scientific and clinical
  rationale for first-in-class molecular targets
  emerged. Furthermore, clear frontrunners were
  identified by integrating analyses to assess the
  accessibility of molecular targets for
  therapeutic compounds, the size of the target
  patient population that would benefit from
  therapeutic intervention, and the expected
  positioning of the first-in-class products based
  on the molecular targets and mechanisms of action
  of currently marketed products .
• These insights and a detailed review of the
  available evidence from scientific studies
  substantiate the perspective that
  first-in-class-product technology in its own
  right is not sufficient to offer a compelling
  scientific and clinical rationale. However, a
  range of products offer very significant
  scientific and clinical promise and could
  therefore result in a strong commercial
  proposition with the prospect of clinically and
  commercially transformative products in the
  future.
• Read The Complete Report On http//www.bigmarket
  research.com/frontier-pharma-prostate-cancer-ident
  ifying-and-commercializing-first-in-class-innovati
  on-market

5
Key Market

• A Deals Landscape with Numerous Investment
  Opportunities
• Analysis has confirmed that 169 of the 174
  first-in-class products have not been involved in
  a licensing or co-development deal. Although many
  act on targets that are not yet strongly
  substantiated in terms of their therapeutic
  potential in prostate cancer in clinical studies,
  there are many which are supported by promising
  in vivo and in vitro preclinical evidence, and as
  such are highly promising prostate cancer
  therapies. Indeed, breakthrough innovations are
  highly desirable as an investment option.
• However, most deals involving first-in-class
  products were either preclinical or Phase I
  development, whereas advance-in-class and
  addition-to-class product deals were typically
  made in Phases II and III, therefore showing
  significant differentiation. These findings have
  significant strategic implications for both
  biotech companies seeking to out-license products
  and firms with an interest in in-licensing
  first-in-class products with strong clinical and
  commercial prospects.

6
Scope

• The report analyzes innovation in prostate
  cancer, in the context of the overall pipeline
  and current market landscape. In addition, it
  analyzed the deals landscape surrounding
  first-in-class products in prostate cancer, and
  pinpoints opportunities for in-licensing. The
  report covers and includes
• A brief introduction to prostate cancer,
  including symptoms, pathophysiology, and overview
  of pharmacotherapy and treatment algorithms.
• The changing molecular target landscape between
  market and pipeline and particular focal points
  of innovation in the pipeline.
• Comprehensive review of the pipeline for
  first-in-class therapies, analyzed on the basis
  of stage of development, molecule type and
  molecular target.
• Identification and assessment of first-in-class
  molecular targets with a particular focus on
  early-stage programs of which clinical utility
  has yet to be evaluated, as well as literature
  reviews on novel molecular targets.
• Assessment of the licensing and co-development
  deal landscape for prostate cancer therapies and
  benchmarking of deals involving first-in-class
  versus non-first-in-class-products.

7
Reasons to buy

• The report will assist business development and
  enable marketing executives to strategize their
  product launches, by allowing them to
• Understanding of the focal shifts in molecular
  targets in the prostate cancer pipeline.
• Understanding of the distribution of pipeline
  programs by phase of development, molecule type
  and molecular target.
• Access a scientific and clinical analysis of
  first-in-class developmental programs for
  prostate cancer, benchmarked against
  non-first-in-class targets.
• Access a list of the first-in-class therapies
  potentially open to deal-making opportunities
• To get More Details Enquire _at_

8
Table Of Content

• Executive Summary
• The Case for Innovation in Prostate Cancer
• Clinical and Commercial Landscape
• Assessment of Pipeline Product Innovation
• Signaling Network, Disease Causation and
  Innovation Alignment
• First-in-Class Target and Pipeline Program
  Evaluation
• Pipeline Programs Targeting Aurora Kinase
• Deals and Strategic Consolidations
• Appendix
• Read The Complete TOC _at_ http//www.bigmarketresear
  ch.com/frontier-pharma-prostate-cancer-identifying
  -and-commercializing-first-in-class-innovation-mar
  ket

9
Contact Us
Deep Joshi 5933 NE Win Sivers Drive, 205,
Portland, OR 97220 United States Direct 1
[phone] Toll Free 1 [phone] Fax
1 [phone] Email help_at_bigmarketresearch
.com Web http//www.bigmarketresearch.com